February 22, 2022

VDH COVID-19 Therapeutics Bi-Weekly Update

Total Allocations to Monoclonal Antibody Administration Sites (last allocation cycle as of 02/16/2022):

<table>
<thead>
<tr>
<th>Monoclonal Antibody</th>
<th>Central</th>
<th>Eastern</th>
<th>Northern</th>
<th>Northwest</th>
<th>Southwest</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sotrovimab</td>
<td>66</td>
<td>42</td>
<td>0</td>
<td>234</td>
<td>432</td>
<td>774</td>
</tr>
<tr>
<td>Evusheld</td>
<td>96</td>
<td>48</td>
<td>288</td>
<td>312</td>
<td>24</td>
<td>768</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>162</strong></td>
<td><strong>90</strong></td>
<td><strong>288</strong></td>
<td><strong>546</strong></td>
<td><strong>456</strong></td>
<td><strong>1542</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral Antiviral*</th>
<th>Central</th>
<th>Eastern</th>
<th>Northern</th>
<th>Northwest</th>
<th>Southwest</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paxlovid</td>
<td>380</td>
<td>600</td>
<td>120</td>
<td>320</td>
<td>480</td>
<td>1,900</td>
</tr>
<tr>
<td>Molnupiravir</td>
<td>1,176</td>
<td>1,056</td>
<td>2,232</td>
<td>1,344</td>
<td>1,800</td>
<td>7,608</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,556</strong></td>
<td><strong>1,656</strong></td>
<td><strong>2,352</strong></td>
<td><strong>1,664</strong></td>
<td><strong>2,280</strong></td>
<td><strong>9,508</strong></td>
</tr>
</tbody>
</table>

(*Oral Antiviral numbers presented do not include those allocated to CPESN)

**Newly Granted FDA EUA for Bebtelovimab**
- The FDA granted an EUA for the Eli Lilly product, Bebtelovimab on 02/11/2022
- Bebtelovimab is a monoclonal antibody authorized for the treatment of active mild-to-moderate COVID-19 in patients 12 years of age and older that are at high risk for progression to severe COVID-19
- For more information on Bebtelovimab, please review the FDA’s [fact sheet for healthcare providers](#)

**Reporting Requirements for Therapeutics Usage & Inventory**
- Sites that are not compliant with reporting after February 21st will begin to receive a notification on the need to report and may not have their orders fulfilled until they report.
- Reporting for Sotrovimab is **due every Wednesday by 11:59PM ET** in the U.S. Healthcare COVID-19 Portal (i.e., TeleTracking/NHSN)
- VDH has published a job aid for reporting into the U.S. Healthcare COVID-19 Portal, which can be accessed [here](#)
- Reporting courses administered and daily on-hand for Paxlovid, Molnupiravir, Evusheld and Bebtelovimab are **due daily by 11:59pm EDT** in the [HHS Health Partner Order Portal (HPoP)](#).
- VDH has published a job aid for reporting into the HHS Health Partner Order Portal (HPoP) [here](#)
- **If you are having challenges with reporting or have questions, please contact COVID19Therapeutics@vdh.virginia.gov** for assistance.

**Bam/ETE and Regen-COV Monoclonal Antibody Information Reminder**
- The return of Bam/ETE and Regen-COV is not recommended; any returned product has to be destroyed
- COVID-19 environment remains dynamic
- Products may be effective against future variants

**Therapeutics Storage Reminder**
- If you have storage concerns or challenges:
  - Consider transferring products to another location/site in your region or health system
  - If your facility does not have the appropriate storage space and you would like to transfer product, please contact covid19therapeutics@vdh.virginia.gov
- While it is **NOT** recommended, if product **MUST** be returned:
  - For Bam/ETE, see The Lilly Return Goods Procedure; detailed guidance can be found at: [https://www.lillytrade.com/](https://www.lillytrade.com/)
For Regen-COV, call 844-734-6643

Note: Reconstituted (diluted product) SHOULD NOT be returned and should be treated as waste per your facility’s SOP

**Therapeutics Requests in VaxMaX**

- In addition to the other available Therapeutics, Paxlovid and Molnupiravir can now be requested through [VaxMaX](#). Once logged into your VaxMaX account, go to the Provider Portal tab, and click “Request Therapeutics”.
- Federal Retail Pharmacy Partners (FRPP) cannot request Therapeutics and must enroll with their retail pharmacy chain to do so.
- When requesting Therapeutics, request based on the number of courses you would like your facility to receive.
- Only pharmacies, healthcare facilities with pharmacies or facilities with a “Physician Selling Controlled Substances Facility Permit”, issued by the Virginia Board of Pharmacy, may order Paxlovid or Molnupiravir through VaxMax.

**Greater Sotrovimab and Paxlovid Availability**

- Please note that due to a decrease in COVID-19 cases, the demand for therapeutics has lessened and there is a greater availability of both Paxlovid and Sotrovimab.

**Updates to the VDH COVID-19 Treatment Locator Tool Reminder**

- Please find the locator tool here: [COVID-19 Treatment Locator - Monoclonal Antibodies (virginia.gov)](https://www.virginia.gov/covid-19-treatment-locator/)
- If you are not listed on the Locator Tool and provide appointments to the public, please email covid19therapeutics@vdh.virginia.gov

**Upcoming Therapeutics Webinar Details**

- Registration links:
  - **Wednesday, 02/23/2022 from 12-1PM**